Enhanced nucleotide excision repair capacity in lung cancer cells by preconditioning with DNA-damaging agents

Oncotarget

Volumn 6, Issue 26, 2015, Pages 22575-22586

  Choi, Ji Ye ^a   Park, Jeong Min ^a   Yi, Joo Mi ^b   Leem, Sun Hee ^a   Kang, Tae Hong ^a  

^a Dong A University   (South Korea)

^b Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

Chemoresistance; Nucleotide excision repair; SIRT1; XPA

Indexed keywords

ATR PROTEIN; CISPLATIN; SIRTUIN 1; XERODERMA PIGMENTOSUM GROUP A PROTEIN; DNA; DNA BINDING PROTEIN; MONOCLONAL ANTIBODY; PYRIMIDINE DIMER;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME INHIBITION; EXCISION REPAIR; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN ACETYLATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION; UPREGULATION; DNA REPAIR; DRUG EFFECTS; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; PYRIMIDINE DIMERS;

EID: 84941200823     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4610     Document Type: Article

References (31)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH G. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England journal of medicine. 2002; 346:92-98.
2. Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chemical reviews. 1999; 99:2467-2498.
3. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nature reviews Drug discovery. 2005; 4:307-320.
4. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews Cancer. 2007; 7:573-584.
5. Bowden NA. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer letters. 2014; 346:163-171.
6. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New England journal of medicine. 2006; 355:983-991.
7. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:1291-1295.
8. Costa RM, Chigancas V, Galhardo Rda S, Carvalho H, Menck CF. The eukaryotic nucleotide excision repair pathway. Biochimie. 2003; 85:1083-1099.
9. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Molecular cancer. 2005; 4:18.
10. Honecker F, Mayer F, Stoop H, Oosterhuis JW, Koch S, Bokemeyer C, Looijenga LH. Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors. Laboratory investigation; a journal of technical methods and pathology. 2003; 83:1489-1495.
11. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope CG, Kohn EC, Davidson B. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005; 103:2313-2319.
12. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. International journal of cancer Journal international du cancer. 2004; 110:352-361.
13. Mendoza J, Martinez J, Hernandez C, Perez-Montiel D, Castro C, Fabian-Morales E, Santibanez M, Gonzalez-Barrios R, Diaz-Chavez J, Andonegui MA, Reynoso N, Onate LF, Jimenez MA, Nunez M, Dyer R, Herrera LA. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. British journal of cancer. 2013; 109:68-75.
14. Kang TH, Reardon JT, Sancar A. Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein. Nucleic acids research. 2011; 39:3176-3187.
15. Mitchell DL. The relative cytotoxicity of (6-4) photoproducts and cyclobutane dimers in mammalian cells. Photochemistry and photobiology. 1988; 48:51-57.
16. Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:2864-2867.
17. Kang TH, Sancar A. Circadian regulation of DNA excision repair: implications for chrono-chemotherapy. Cell cycle. 2009; 8:1665-1667.
18. Lee TH, Park JM, Leem SH, Kang TH. Coordinated regulation of XPA stability by ATR and HERC2 during nucleotide excision repair. Oncogene. 2014; 33:19-25.
19. Kang TH, Lindsey-Boltz LA, Reardon JT, Sancar A. Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:4890-4895.
20. Fan W, Luo J. SIRT1 regulates UV-induced DNA repair through deacetylating XPA. Molecular cell. 2010; 39:247-258.
21. Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, Sen Gupta T, Nilsen H, Mitchell JR, Croteau DL, Bohr VA. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell. 2014; 157:882-896.
22. Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, Limmroth V, Thomale J. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2007; 27:9451-9457.
23. Gertz M, Fischer F, Nguyen GT, Lakshminarasimhan M, Schutkowski M, Weyand M, Steegborn C. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:E2772-2781.
24. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochemical pharmacology. 2013; 85:1219-1226.
25. Cheung-Ong K, Giaever G, Nislow C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chemistry & biology. 2013; 20:648-659.
26. Cramers P, Filon AR, Pines A, Kleinjans JC, Mullenders LH, van Zeeland AA. Enhanced nucleotide excision repair in human fibroblasts pre-exposed to ionizing radiation. Photochemistry and photobiology. 2012; 88:147-153.
27. Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, Dong H, Wei J, Song J, Zhang DD, Fang D. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Molecular cell. 2012; 46:484-494.
28. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004; 303:2011-2015.
29. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature. 2008; 451:587-590.
30. Reardon JT, Sancar A. Purification and characterization of Escherichia coli and human nucleotide excision repair enzyme systems. Methods in enzymology. 2006; 408:189-213.
31. Joh HM, Choi JY, Kim SJ, Chung TH, Kang TH. Effect of additive oxygen gas on cellular response of lung cancer cells induced by atmospheric pressure helium plasma jet. Scientific reports. 2014; 4:6638.